Pediatric NHL trials
| Reference . | Trial acronym . | Stage . | Treatment . | EFS . | OS . | ||
|---|---|---|---|---|---|---|---|
| Survival . | % . | Survival . | % . | ||||
| B-cell NHL (BL, DLBCL, PMBCL) | |||||||
| 103 | FAB LMB96 | I and II (localized disease) | COPAD × 2 | 4-y | 98.3 | ||
| COP, COPADM 1-2, CYM, M1 | 4-y | 91.9 | |||||
| COP, COPADM 1-2, CYM, no M1 | 4-y | 92.5 | |||||
| 104 | FAB LMB96 | III and IV (advanced CNS negative) | COP, COPADM 1-2, CYVE, M1-M4 | 4-y | 90 | ||
| COP, COPADM 1-2, mini-CYVE, M1 | 4-y | 80 | |||||
| 105 | FAB LMB96 | All advanced, including CNS positive | COP, COPADM1+2, CYVE 1+2, M1, M2, M3, M4, CNS-positive patients received 13 IT injections plus an additional course of high-dose methotrexate between CYVE cycles | 4-y | 79 | 4-y | 82 |
| 106 | NHL-BFM 95 | I, II (R1, resected) | A, B | 3-y | 94 | ||
| I, II (R2, not resected), III (LDH <500 U/L) | VA, B, A, B | 3-y | 94 | ||||
| III (R3, LDH 500 to <1000 U/L) | V, AA, BB, CC, AA, BB | 3-y | 85 | ||||
| IV (LDH <1000 U/L, CNS negative) | |||||||
| III, IV (R4, LDH ≥1000 U/L and/or CNS positive) | V, AA, BB, CC, AA, BB, CC | 3-y | 81 | ||||
| 104 | FAB LMB96 | PMBCL | 5-y | 66 | 5-y | 73 | |
| 66 | NHL-BFM 04 | PMBCL | DA-EPOCH-R | 2-y | 92 | 2-y | 92 |
| T-cell NHL (ALCL) | |||||||
| 83,107 | NHL-BFM 90 | I, II-r I-, II-nr, III, IV | Prophase: dexamethasone, cyclophosphamide, ifosfamide, doxorubicin, high-dose methotrexate (5 g/m2) vs methotrexate (0.5 g/m2), cytarabine, etoposide ± vinblastine | 2-y | 75 | ||
| Reference . | Trial acronym . | Stage . | Treatment . | EFS . | OS . | ||
|---|---|---|---|---|---|---|---|
| Survival . | % . | Survival . | % . | ||||
| B-cell NHL (BL, DLBCL, PMBCL) | |||||||
| 103 | FAB LMB96 | I and II (localized disease) | COPAD × 2 | 4-y | 98.3 | ||
| COP, COPADM 1-2, CYM, M1 | 4-y | 91.9 | |||||
| COP, COPADM 1-2, CYM, no M1 | 4-y | 92.5 | |||||
| 104 | FAB LMB96 | III and IV (advanced CNS negative) | COP, COPADM 1-2, CYVE, M1-M4 | 4-y | 90 | ||
| COP, COPADM 1-2, mini-CYVE, M1 | 4-y | 80 | |||||
| 105 | FAB LMB96 | All advanced, including CNS positive | COP, COPADM1+2, CYVE 1+2, M1, M2, M3, M4, CNS-positive patients received 13 IT injections plus an additional course of high-dose methotrexate between CYVE cycles | 4-y | 79 | 4-y | 82 |
| 106 | NHL-BFM 95 | I, II (R1, resected) | A, B | 3-y | 94 | ||
| I, II (R2, not resected), III (LDH <500 U/L) | VA, B, A, B | 3-y | 94 | ||||
| III (R3, LDH 500 to <1000 U/L) | V, AA, BB, CC, AA, BB | 3-y | 85 | ||||
| IV (LDH <1000 U/L, CNS negative) | |||||||
| III, IV (R4, LDH ≥1000 U/L and/or CNS positive) | V, AA, BB, CC, AA, BB, CC | 3-y | 81 | ||||
| 104 | FAB LMB96 | PMBCL | 5-y | 66 | 5-y | 73 | |
| 66 | NHL-BFM 04 | PMBCL | DA-EPOCH-R | 2-y | 92 | 2-y | 92 |
| T-cell NHL (ALCL) | |||||||
| 83,107 | NHL-BFM 90 | I, II-r I-, II-nr, III, IV | Prophase: dexamethasone, cyclophosphamide, ifosfamide, doxorubicin, high-dose methotrexate (5 g/m2) vs methotrexate (0.5 g/m2), cytarabine, etoposide ± vinblastine | 2-y | 75 | ||
All medications are part of systemic therapy unless otherwise indicated. Treatment course A: dexamethasone, vincristine, ifosfamide, cytarabine, etoposide, methotrexate (1 g/m2), and intrathecal methotrexate (12 mg) + intrathecal cytarabine (30 mg) + intrathecal prednisolone (10 mg); intrathecal doses adjusted for age in patients <3 years. Treatment course B: dexamethasone, vincristine, cyclophosphamide, doxorubicin, methotrexate (1 g/m2), and intrathecal methotrexate (12 mg) + intrathecal cytarabine (30 mg) + intrathecal prednisolone (10 mg); intrathecal doses adjusted for age in patients <3 years. Treatment courses AA and BB are the same as A and B, respectively, with the following dose adjustments: methotrexate (5 g/m2) and intrathecal methotrexate (6 mg) + intrathecal cytarabine (15 mg) + intrathecal prednisolone (5 mg); intrathecal doses adjusted for age in patients <3 years. Treatment course CC: dexamethasone, vindesine, cytarabine, etoposide, intrathecal methotrexate (12 mg) + intrathecal cytarabine (30 mg) + intrathecal prednisolone (10 mg).
COP, cyclophosphamide, vincristine, and prednisone; COPAD, cyclophosphamide, vincristine, prednisone, and doxorubicin; COPADM, cyclophosphamide, vincristine, prednisone, doxorubicin, and high-dose methotrexate (8 g/m2); CYM, cyclophosphamide, high-dose cytarabine, and high-dose methotrexate; CYVE, cytarabine, high-dose cytarabine (3 g/m2), etoposide (200 mg/m2), and dexamethasone; LDH, lactate dehydrogenase; LMB, Lymphoma Malins de Burkitt; M1, COPADM plus intrathecal methotrexate, cytarabine, and hydrocortisone; M2, cytarabine and etoposide; M3, cyclophosphamide, vincristine, prednisone, and doxorubicin; M4, cytarabine and etoposide; mini-CYVE, cytarabine, high-dose cytarabine (2 g/m2), etoposide (100 mg/m2), and dexamethasone; NR, not resected; R, resected; R1, stage I + II resected; R2, stage I + II not resected, stage III: LDH <500 U/L; R3, stage III: LDH 500 to <1000 U/L, stage IV: BM+ and LDH <1000 U/L; R4, stage III + IV: LDH ≥1000 U/L and/or CNS+; V, dexamethasone, and cyclophosphamide.